Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
NAD+ is a coenzyme found in every cell in the body, essential for mitochondrial function, DNA repair, and cellular energy production. NAD+ levels decline with age, and supplementation has become popular in longevity, performance, and addiction recovery contexts.
The compound is most commonly administered in three forms:
- NAD+ direct: the active molecule itself, given via injection (subcutaneous, intramuscular, or IV infusion)
- NMN (Nicotinamide Mononucleotide): a precursor, taken orally or sublingually
- NR (Nicotinamide Riboside): another precursor, FDA-cleared as a dietary supplement
This entry focuses on NAD+ direct administration. NMN and NR have separate entries.
NAD+ research is genuinely interesting but the supplementation evidence is mixed. What's well-established: NAD+ levels decline with age in most tissues; NAD+ is essential for sirtuin function, DNA repair, and energy metabolism; increasing cellular NAD+ via precursors does demonstrably raise blood NAD+ levels. What's NOT well-established: whether direct NAD+ injections (vs precursors) provide meaningful tissue-level benefit, since NAD+ is too large to cross cell membranes directly; whether raising NAD+ levels translates to measurable health, performance, or longevity outcomes in humans; long-term safety of supraphysiological NAD+ administration; whether subjective benefits represent real effects or expectation/placebo.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Subcutaneous injection | Short (minutes for direct NAD+) |
| Intramuscular injection | Short (minutes for direct NAD+) |
| IV infusion (clinical) | Short (minutes for direct NAD+) |
| Intranasal (experimental) | Limited data |
What it does
Main effects
- Energy and performance: reduced fatigue, improved cognitive function, enhanced workout recovery
- Longevity protocols: based on research showing declining NAD+ levels with age and improved mitochondrial function with supplementation
- Addiction recovery: IV NAD+ infusions used clinically for opioid, alcohol, and stimulant withdrawal (with limited but interesting clinical evidence)
- Post-illness recovery: used in long-COVID and chronic fatigue contexts
- Cognitive enhancement: anecdotal reports of mental clarity and focus
What to watch for
Common side effects
- Acute IV infusion symptoms: chest tightness, flushing, nausea, headache during administration (common with IV; less with SubQ/IM)
- Injection-site reactions: redness, irritation at site
- Sleep disruption if taken late in the day
- Headache in some users
- Limited long-term safety data: supraphysiological doses with unknown chronic effects on sirtuin activity and cellular signaling
- Source quality concerns: regulatory gray area; purity and sterility vary by source
Key facts
Key facts worth knowing
- NAD+ itself doesn't easily enter cells. Direct injections may primarily work by being broken down into precursors (NMN, NR) that DO enter cells, meaning oral NMN/NR may be equivalent or better than expensive injections at a fraction of the cost.
- NAD+ levels decline with age in most tissues. NAD+ is essential for sirtuin function, DNA repair, and energy metabolism. Increasing cellular NAD+ via precursors does demonstrably raise blood NAD+ levels. Whether this translates to measurable health or longevity outcomes in humans is not well-established.
- IV infusion side effects are common and can be significant: chest tightness, flushing, nausea, and headache during administration. These are acute and administration-rate-dependent rather than idiosyncratic reactions.
- The cost difference between direct NAD+ injection and oral precursors is substantial, and comparative effectiveness data doesn't currently justify the price differential for most users.
- NAD+ supports sirtuin activity, which affects gene expression broadly. Long-term effects on cancer risk are unknown (sirtuins have complex roles in cell proliferation). Interactions with chemotherapy and certain medications haven't been well-studied.
- Injectable NAD+ exists in a regulatory gray area. There is no FDA-approved injectable NAD+ product, so the identity, concentration and sterility of injectable material are unverified. Some products are pH-unstable and degrade quickly after reconstitution.
Legal status
Legal status
Not approved as a drug by the FDA. NAD+ injections sold via IV clinics and compounding pharmacies in a legal gray area. Precursors (NMN, NR) are sold as supplements with contested regulatory status (FDA has challenged NMN's supplement status). Injectable forms typically require prescription via compounding pharmacies. NR (nicotinamide riboside) sold OTC. Not WADA-prohibited. Not a DEA controlled substance.